Pernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15
08. Mai 2017 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) a specialty pharmaceutical company, announced today that the Company will report financial results...
Pernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Strength
01. Mai 2017 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 01, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that, due to...
Pernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
28. März 2017 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced financial...
Pernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March 28
15. März 2017 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., March 15, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today that...
Pernix Therapeutics Prevails in Zohydro® ER ANDA Litigation
23. Februar 2017 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today that...
Pernix Therapeutics Provides Update on Arbitration
03. Februar 2017 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today provided an...
Pernix Therapeutics Appoints Ken Piña as General Counsel and Chief Compliance Officer
06. Januar 2017 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on pain and CNS conditions, today announced the...
Pernix Therapeutics Appoints New Board Member
22. November 2016 06:30 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced the...
Pernix Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update
10. November 2016 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
Net Revenue Increased 13% Sequentially Over Second Quarter 2016Prescription Volumes Grew Sequentially and Year-Over-Year for All Three Core Brands, Treximet®, Zohydro ER® with BeadTek™ and...
Pernix Therapeutics Appoints Two Board Members
07. November 2016 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced the...